Cargando…
Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study
BACKGROUND: Basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) are benign and malignant, basaloid salivary gland neoplasms, respectively. These tumors show a dual-cell proliferation of inner luminal/ductal cells and outer abluminal/myoepithelial or basal cells. The only difference between...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064148/ https://www.ncbi.nlm.nih.gov/pubmed/30053869 http://dx.doi.org/10.1186/s13000-018-0726-8 |
_version_ | 1783342675672432640 |
---|---|
author | Oyama, Yuzo Nishida, Haruto Kusaba, Takahiro Kadowaki, Hiroko Arakane, Motoki Wada, Junpei Urabe, Shogo Hirano, Takashi Kawano, Kenji Suzuki, Masashi Yokoyama, Shigeo Daa, Tsutomu |
author_facet | Oyama, Yuzo Nishida, Haruto Kusaba, Takahiro Kadowaki, Hiroko Arakane, Motoki Wada, Junpei Urabe, Shogo Hirano, Takashi Kawano, Kenji Suzuki, Masashi Yokoyama, Shigeo Daa, Tsutomu |
author_sort | Oyama, Yuzo |
collection | PubMed |
description | BACKGROUND: Basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) are benign and malignant, basaloid salivary gland neoplasms, respectively. These tumors show a dual-cell proliferation of inner luminal/ductal cells and outer abluminal/myoepithelial or basal cells. The only difference between them is defined as a malignant morphology such as invasion. Recently, the nuclear expression of β-catenin and a catenin beta-1 (CTNNB1) mutation were found in BCA. Transducin-like enhancer of split 1 (TLE1) belongs to the Groucho/TLE family, and it functions in the “off” state in the Wnt/β-catenin signaling pathway. We hypothesized that if the dysregulation of the Wnt/β-catenin signaling pathway could be attributed to the tumorigenesis of BCA/BCAC, there might be differences in TLE1 expression between BCA and BCAC. METHOD: The study included 35 BCA and 4 BCAC cases. We performed immunohistochemistry to detect TLE1 and β-catenin and investigated the catenin beta-1 (CTNNB1) mutational profile among BCA and BCAC cases. RESULTS: In BCA, the expression of TLE1 was confined to luminal cells of glandular structures, in contrast to the expression of β-catenin in abluminal cells. The BCA cases harbored CTNNB1 gene mutations (12/35). In BCAC, luminal cell staining of TLE1 was identical to BCA in non-invasive areas (4/4) but indistinct in invasive areas (3/4). The BCAC cases were β-catenin positive for abluminal cells in both areas. The BCAC cases had CTNNB1 mutation (2/4) and the laser-captured microdissection allowed the separate collection of infiltrative and non-infiltrative areas to detect the same mutation. CONCLUSIONS: Immunohistochemical analysis for TLE1 can identify BCA and BCAC by luminal cell staining difference, especially indistinct luminal cell expression for TLE1 in invasive areas of BCAC. Moreover, TLE1 can be luminal/ductal cell markers. |
format | Online Article Text |
id | pubmed-6064148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60641482018-08-01 Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study Oyama, Yuzo Nishida, Haruto Kusaba, Takahiro Kadowaki, Hiroko Arakane, Motoki Wada, Junpei Urabe, Shogo Hirano, Takashi Kawano, Kenji Suzuki, Masashi Yokoyama, Shigeo Daa, Tsutomu Diagn Pathol Research BACKGROUND: Basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) are benign and malignant, basaloid salivary gland neoplasms, respectively. These tumors show a dual-cell proliferation of inner luminal/ductal cells and outer abluminal/myoepithelial or basal cells. The only difference between them is defined as a malignant morphology such as invasion. Recently, the nuclear expression of β-catenin and a catenin beta-1 (CTNNB1) mutation were found in BCA. Transducin-like enhancer of split 1 (TLE1) belongs to the Groucho/TLE family, and it functions in the “off” state in the Wnt/β-catenin signaling pathway. We hypothesized that if the dysregulation of the Wnt/β-catenin signaling pathway could be attributed to the tumorigenesis of BCA/BCAC, there might be differences in TLE1 expression between BCA and BCAC. METHOD: The study included 35 BCA and 4 BCAC cases. We performed immunohistochemistry to detect TLE1 and β-catenin and investigated the catenin beta-1 (CTNNB1) mutational profile among BCA and BCAC cases. RESULTS: In BCA, the expression of TLE1 was confined to luminal cells of glandular structures, in contrast to the expression of β-catenin in abluminal cells. The BCA cases harbored CTNNB1 gene mutations (12/35). In BCAC, luminal cell staining of TLE1 was identical to BCA in non-invasive areas (4/4) but indistinct in invasive areas (3/4). The BCAC cases were β-catenin positive for abluminal cells in both areas. The BCAC cases had CTNNB1 mutation (2/4) and the laser-captured microdissection allowed the separate collection of infiltrative and non-infiltrative areas to detect the same mutation. CONCLUSIONS: Immunohistochemical analysis for TLE1 can identify BCA and BCAC by luminal cell staining difference, especially indistinct luminal cell expression for TLE1 in invasive areas of BCAC. Moreover, TLE1 can be luminal/ductal cell markers. BioMed Central 2018-07-27 /pmc/articles/PMC6064148/ /pubmed/30053869 http://dx.doi.org/10.1186/s13000-018-0726-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Oyama, Yuzo Nishida, Haruto Kusaba, Takahiro Kadowaki, Hiroko Arakane, Motoki Wada, Junpei Urabe, Shogo Hirano, Takashi Kawano, Kenji Suzuki, Masashi Yokoyama, Shigeo Daa, Tsutomu Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study |
title | Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study |
title_full | Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study |
title_fullStr | Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study |
title_full_unstemmed | Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study |
title_short | Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study |
title_sort | difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064148/ https://www.ncbi.nlm.nih.gov/pubmed/30053869 http://dx.doi.org/10.1186/s13000-018-0726-8 |
work_keys_str_mv | AT oyamayuzo differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT nishidaharuto differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT kusabatakahiro differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT kadowakihiroko differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT arakanemotoki differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT wadajunpei differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT urabeshogo differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT hiranotakashi differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT kawanokenji differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT suzukimasashi differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT yokoyamashigeo differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy AT daatsutomu differenceintransducinlikeenhancerofsplit1proteinexpressionbetweenbasalcelladenomasandbasalcelladenocarcinomasanimmunohistochemicalstudy |